NasdaqGS - Delayed Quote USD

CytomX Therapeutics, Inc. (CTMX)

1.5900 -0.0100 (-0.62%)
At close: April 26 at 4:00 PM EDT
1.5900 0.00 (0.00%)
After hours: April 26 at 4:05 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
101,214.0000
101,214.0000
53,163.0000
37,312.0000
68,427.0000
Operating Expense
107,698.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
Operating Income
-6,484.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
Net Non Operating Interest Income Expense
9,837.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
Other Income Expense
-30.0000
-30.0000
340.0000
-83.0000
-27.0000
Pretax Income
3,323.0000
3,323.0000
-99,317.0000
-115,870.0000
-78,731.0000
Tax Provision
3,892.0000
3,892.0000
--
--
-13,911.0000
Net Income Common Stockholders
-569.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Diluted NI Available to Com Stockholders
-569.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Basic EPS
-0.01
--
-1.51
-1.81
-1.40
Diluted EPS
-0.01
--
-1.51
-1.81
-1.40
Basic Average Shares
73,808.2370
--
65,739.8440
64,146.8480
46,145.5630
Diluted Average Shares
73,808.2370
--
65,739.8440
64,146.8480
46,145.5630
Total Operating Income as Reported
-6,484.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
Total Expenses
107,698.0000
107,698.0000
154,498.0000
153,354.0000
148,967.0000
Net Income from Continuing & Discontinued Operation
-569.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Normalized Income
-569.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Interest Income
9,837.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
Net Interest Income
9,837.0000
9,837.0000
1,678.0000
255.0000
1,836.0000
EBIT
-6,484.0000
-6,484.0000
-101,335.0000
-116,042.0000
-80,540.0000
EBITDA
-4,309.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
Reconciled Depreciation
2,175.0000
2,175.0000
2,443.0000
2,706.0000
2,573.0000
Net Income from Continuing Operation Net Minority Interest
-569.0000
-569.0000
-99,317.0000
-115,870.0000
-64,820.0000
Normalized EBITDA
-4,309.0000
-4,309.0000
-98,892.0000
-113,336.0000
-77,967.0000
Tax Rate for Calcs
0.0002
0.0002
--
--
0.0002
12/31/2020 - 10/8/2015

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ASMB Assembly Biosciences, Inc.
12.65
-5.31%
 
SPRO Spero Therapeutics, Inc.
1.4600
+2.10%
 
NXTC NextCure, Inc.
1.3500
+4.65%
 
EIGRQ Eiger BioPharmaceuticals, Inc.
2.6700
-12.17%
 
ALGS Aligos Therapeutics, Inc.
0.7820
-4.40%
 
GLPG.AS Galapagos NV
26.68
+0.45%
 
CLRB Cellectar Biosciences, Inc.
3.0300
+0.33%
 
TIL Instil Bio, Inc.
10.60
+2.02%
 
NUVB Nuvation Bio Inc.
2.6800
+2.29%
 
AVRO AVROBIO, Inc.
1.2100
+2.11%